A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance
International Journal of Molecular Sciences · 14.04.2023 · 24 (8) · 7238
DOI: 10.3390/ijms24087238 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.04.2023. Verfasst von Luis Vergara-Gómez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Biomedicine and Translational Research Laboratory, Centre of Excellence in Translational Medicine and Scientific and Technological Bioresource Nucleu…. Hauptthemen laut MEDLINE: Gallbladder Neoplasms, Carcinoma in Situ. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondo Nacional de Desarrollo Científico y Tecnológico, Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias, ANID/FONDECYT.
Abstract (Originalsprache)
Treatment options for advanced gallbladder cancer (GBC) are scarce and usually rely on cytotoxic chemotherapy, but the effectiveness of any regimen is limited and recurrence rates are high. Here, we investigated the molecular mechanisms of acquired resistance in GBC through the development and characterization of two gemcitabine-resistant GBC cell sublines (NOZ GemR and TGBC1 GemR). Morphological changes, cross-resistance, and migratory/invasive capabilities were evaluated. Then, microarray-based transcriptome profiling and quantitative SILAC-based phosphotyrosine proteomic analyses were performed to identify biological processes and signaling pathways dysregulated in gemcitabine-resistant GBC cells. The transcriptome profiling of parental and gemcitabine-resistant cells revealed the dysregulation of protein-coding genes that promote the enrichment of biological processes such as epithelial-to-mesenchymal transition and drug metabolism. On the other hand, the phosphoproteomics analysis of NOZ GemR identified aberrantly dysregulated signaling pathways in resistant cells as well as active kinases, such as ABL1, PDGFRA, and LYN, which could be novel therapeutic targets in GBC. Accordingly, NOZ GemR showed increased sensitivity toward the multikinase inhibitor dasatinib compared to parental cells. Our study describes transcriptome changes and altered signaling pathways occurring in gemcitabine-resistant GBC cells, which greatly expands our understanding of the underlying mechanisms of acquired drug resistance in GBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedicine and Translational Research Laboratory, Centre of Excellence in Translational Medicine and Scientific and Technological Bioresource Nucleus (CEMT-BIOREN), Universidad de La Frontera, Temuco 4810296, Chile.
- School of Medicine, Department of Pathology, Pontificia Universidad Católica de Chile, Santiago 8330024, Chile.
- Center for Cancer Prevention and Control (CECAN), Pontificia Universidad Católica de Chile, Santiago 8331150, Chile.
- Delta Omics Biotechnology, Rockville, MD 20855, USA.
- Department of Basic Sciences, Universidad de La Frontera, Temuco 4810296, Chile.
- Laboratory of Integrative Biology (LIBi), Centre of Excellence in Translational Medicine and Scientific and Technological Bioresource Nucleus (CEMT-BIOREN), Universidad de La Frontera, Temuco 4810296, Chile.
ORCID-Profile: Jun Zhong, Carmen Ili, Gabriela Repetto, Juan C Roa, Patricia García
Förderung
- Fondo Nacional de Desarrollo Científico y Tecnológico
- Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias
- ANID/FONDECYT
- ANID/FONDAP
Zitieren
APA
Vergara-Gómez, L., Bizama, C., Zhong, J., Buchegger, K., Suárez, F., Rosa, L., Ili, C., Weber, H., Obreque, J., Espinoza, K., Repetto, G., Roa, J. C., Leal, P., & García, P. (2023). A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance. International Journal of Molecular Sciences, 24(8), 7238. https://doi.org/10.3390/ijms24087238
Vancouver
Vergara-Gómez L, Bizama C, Zhong J, Buchegger K, Suárez F, Rosa L, et al. A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance. International Journal of Molecular Sciences. 2023;24(8):7238. doi:10.3390/ijms24087238
BibTeX
@article{VergaraGmez2023,
author = {Vergara-Gómez, Luis and Bizama, Carolina and Zhong, Jun and Buchegger, Kurt and Suárez, Felipe and Rosa, Lorena and Ili, Carmen and Weber, Helga and Obreque, Javiera and Espinoza, Karena and Repetto, Gabriela and Roa, Juan C and Leal, Pamela and García, Patricia},
title = {A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {8},
pages = {7238},
doi = {10.3390/ijms24087238}
}
EUVIMED